Long-term investors can consider buying the stock now or on dips for a possible target of over Rs 600-650 in the next 12 months which translates into an upside of over 13-22 per cent from Rs 530 recorded on 5 August, suggested experts.
Nifty Pharma, 4 others hit 52-week high since Iran war while Nifty fell 7%. Will the form continue?
Despite a challenging market backdrop fueled by geopolitical tensions and foreign fund outflows, five Indian sectors—Pharma, Energy, Defence, Capital Markets, and Metals—are showing remarkable strength.
May 25, 2026